Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

SLNO·NASDAQ

$53.01

+0.038%
HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$2.76B
EPS0.4100
P/E Ratio117.86
Earnings Date08/05/2026

slno

Cash and Cash Equivalents

Last Annual Value

70.11M

3-Year CAGR

69%

5-Year CAGR

7%

10-Year CAGR

29%

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Competitors Analysis of Cash and Cash Equivalents

SLNO · NASDAQ
CompanyCash and Cash Equivalents
CAGR 3Y
CAGR 5Y
CAGR 10Y
70.11M
-25.5%26.9%38.4% 
434.00M
26.7%7.1%10.4%
893.37M
94.4%34.8%-6.6%
CELC logo
Celcuity Inc.
NASDAQ:CELC
165.70M
75.5%14.5%39.7%
357.33M
63.8%20.8%N/A
165.81M
44.0%44.4%49.0%
131.55M
3.6%N/AN/A
296.68M
1.2%56.8%N/A
Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Fair Value Envelope

SLNO · NASDAQ

Our analysis suggests that SLNO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $53.01, this represents a potential HIDDEN relative to our calculated worth for Soleno Therapeutics, Inc..

Intrinsic Value
Current Price: $53.01